The Manufacturers Life Insurance Company Has $372,000 Holdings in Harrow, Inc. (NASDAQ:HROW)

The Manufacturers Life Insurance Company decreased its holdings in Harrow, Inc. (NASDAQ:HROW) by 4.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,080 shares of the company’s stock after selling 472 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Harrow were worth $372,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Barclays PLC grew its stake in Harrow by 301.9% during the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after buying an additional 39,506 shares in the last quarter. Brookstone Capital Management bought a new stake in Harrow during the fourth quarter worth $275,000. SG Americas Securities LLC lifted its stake in Harrow by 158.5% during the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company’s stock worth $1,030,000 after purchasing an additional 18,815 shares during the last quarter. Sonora Investment Management Group LLC bought a new position in shares of Harrow in the 4th quarter valued at $518,000. Finally, Bank of New York Mellon Corp grew its position in Harrow by 8.4% in the fourth quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company’s stock valued at $2,900,000 after acquiring an additional 6,690 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Up 10.9%

Shares of NASDAQ HROW opened at $28.41 on Friday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock has a market capitalization of $1.04 billion, a PE ratio of -30.22 and a beta of 0.41. Harrow, Inc. has a one year low of $15.97 and a one year high of $59.23. The business’s fifty day moving average price is $25.02 and its 200-day moving average price is $31.91.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The firm had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. On average, equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. B. Riley lowered their price objective on Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. HC Wainwright upped their price target on shares of Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, May 12th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.